34 studies found for:    " June 16, 2010":" July 16, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Completed Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
Condition: Herpes Zoster
Interventions: Biological: Herpes Zoster Vaccine 1437173A;   Biological: Placebo
22 Completed The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers
Conditions: HIV;   Fenofibrate;   Protease Inhibitors;   Hypertriglyceridemia;   Glucuronosyltransferase
Interventions: Drug: Fenofibrate;   Drug: Ritonavir;   Drug: Lopinavir/Ritonavir
23 Recruiting The Use of Leukapheresis to Support HIV Pathogenesis Studies
Condition: HIV
Intervention: Procedure: Leukapheresis
24 Withdrawn A Semi-Factorial Cluster-Randomized Trial to Estimate the Effect Size of Community Mobilization and VCT Vans on the Adoption of Voluntary Counseling and Testing (VCT) Services in Andhra Pradesh, India: THE MCVCT STUDY
Conditions: HIV;   AIDS;   Epidemiology;   Prevention
Intervention:
25 Completed Behavioral Activation/Armodafinil to Treat Fatigue in HIV/AIDS
Conditions: HIV+;   Fatigue;   Goals
Interventions: Behavioral: Behavioral Activation Therapy;   Behavioral: Supportive Counseling
26 Completed Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Tenofovir To Abacavir In Hiv-1-Infected Subjects With Loss Of Bone Mineral Density
Condition: HIV
Intervention: Drug: Switch from tenofovir to abacavir
27 Completed HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.
Conditions: HIV/AIDS;   Sexually Transmitted Infections
Intervention: Behavioral: RESPECT-2 Counseling
28 Unknown  The Study of the Prevalence of Helicobacter Pylori Infection Among HIV/AIDS Cohort
Condition: HIV
Intervention:
29 Terminated MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2)
Condition: HIV-1 Infection
Interventions: Drug: MK6186;   Drug: Comparator: Placebo
30 Completed Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults
Condition: HIV-1 Infections
Interventions: Biological: ChAdV63.HIVconsv low dose.;   Biological: ChAdV63.HIVconsv high dose.;   Biological: pSG2.HIVconsv;   Biological: MVA.HIVconsv;   Other: Placebo
31 Active, not recruiting RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
Conditions: Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Primary CNS Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   HER2-negative Breast Cancer;   HIV-associated Hodgkin Lymphoma;   Intraocular Lymphoma;   Male Breast Cancer;   Nodal Marginal Zone B-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Primary Central Nervous System Hodgkin Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Rectal Cancer;   Recurrent Small Lymphocytic Lymphoma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Colon Cancer;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Rectal Cancer;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Rectal Cancer;   Stage IV Small Lymphocytic Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Drug: capecitabine;   Other: laboratory biomarker analysis
32 Completed Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children
Condition: Malaria
Interventions: Biological: GSK Biological's Investigational Malaria Vaccine 257049;   Biological: Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);;   Biological: Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).
33 Completed Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV Patients
Condition: Tuberculosis
Intervention: Biological: V-5 immunitor
34 Active, not recruiting Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
Conditions: Anal Cancer;   Neoplasm of Uncertain Malignant Potential;   Nonneoplastic Condition;   Precancerous Condition
Interventions: Other: clinical observation;   Procedure: infrared photocoagulation therapy

Show previous page of results Previous Page (1-20) Studies Shown (21-34) Next Page
Indicates status has not been verified in more than two years